The US FDA Launches 5-Year Action Plan for Neurodegenerative Disease
Shots:
- The US FDA unveiled 5yr. action plan to foster drug development & simplifying patient access to novel treatments as well as improve and extends the lives of people suffering from neurodegenerative disease inc. ALS
- This new strategy is part of the accelerating access to critical therapies for ALS Act or ACT for ALS. It includes provisions for the Department of HHS to award grants & contracts to public & private entities for R&D
- The US FDA focuses to understand disease pathogenesis & natural history, support patient access to new drugs and bolster relevant clinical trial infrastructure. Please keep an eye on this space for further details on this topic
Ref: PRNewswire | Image: US FDA
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
